A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

  • End date
    Aug 18, 2022
  • participants needed
  • sponsor
Updated on 7 May 2021
myeloproliferative disorder
blood transfusion


This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion dependence. The study is divided into a Screening Period, a Treatment Period (consisting of a Primary Phase, a Day 169 Disease Response Assessment, and an Extension Phase), followed by a Posttreatment Follow-up Period.


Subjects satisfying the eligibility criteria will be assigned to 1 of the following cohorts (which are enrolling in parallel) based on their eligibility:

  • Cohort 1 (subjects with anemia only that are not currently receiving RBC transfusions) - Cohort 2: (subjects that are RBC-transfusion dependent)
  • Cohort 3A: (subjects on ruxolitinib as part of their standard of care therapy that have anemia only)
  • Cohort 3B: (subjects on ruxolitinib as part of their standard of care therapy that are RBC-transfusion dependent) Overall, the study will enroll approximately 100 subjects worldwide.

Condition Blood disorder, Anemia, Myelosclerosis with myeloid metaplasia, Anemia; Non-Hodgkin’s Lymphoma, Myelofibrosis, Hematological Disorders, anaemia
Treatment Luspatercept
Clinical Study IdentifierNCT03194542
Last Modified on7 May 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Myelofibrosis or Anemia?
Do you have any of these conditions: Myelosclerosis with myeloid metaplasia or Myelofibrosis or Blood disorder or Anemia or Anemia; Non-Hodgkin’s Lymphoma or anaemia or Hematological Diso...?
Do you have any of these conditions: Myelofibrosis or anaemia or Hematological Disorders or Anemia or Myelosclerosis with myeloid metaplasia or Blood disorder or Anemia; Non-Hodgkin’s Lym...?
Do you have any of these conditions: Hematological Disorders or Blood disorder or Anemia or Anemia; Non-Hodgkin’s Lymphoma or anaemia or Myelofibrosis or Myelosclerosis with myeloid metap...?
Subjects must satisfy the following criteria to be enrolled in the study (with
the enrollment date defined as the date in which the subject is assigned a
cohort in Integrated Response Technology [IRT]) and receive their first dose
of luspatercept
Subject is 18 years of age at the time of signing the informed consent form (ICF)
Subject has Myeloproliferative neoplasm (MPN)-associated myelofibrosis (PMF, postPost -polycythemia vera myelofibrosis (PV MF), and/or Post-essential thrombocythemia myelofibrosis (post-ET MF)) as confirmed from the most recent local bone marrow biopsy report according to the World Health Organization 2016 criteria
Subject has anemia defined as
Cohorts 1 and 3A
Obtain 3 Hemoglobin (Hgb) levels of 9.5 g/dL recorded on 3 different days, including the day of dosing, in the 84-day period immediately up to the C1D1 date. There must be 14 days in between each Hgb measurement. No subjects with an interval 42 days between hemoglobin measurements will be enrolled
There must not be any Red blood cell (RBC) transfusions within the 84-day period immediately up to the C1D1 date
Cohorts 2 and 3B
Average RBC-transfusion frequency: 4 to 12 RBC units/84 days immediately up to the C1D1 date. There must be no interval > 56 days without 1 RBC-transfusion
Subjects must have a Hgb value of < 13 g/dL on C1D1 prior to luspatercept administration
Only RBC transfusions given when the Hgb 9.5 g/dL are scored in determining eligibility
Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 2
Subject is not anticipated during the 6 months from the C1D1 date to receive a hematopoietic cell transplant
A female of childbearing potential (FCBP) for this study is defined as a female who
has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). FCBP participating in the study must
Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact
Either commit to true abstinence _from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception_ without interruption, 28 days prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal halflife of luspatercept based on multiple-dose pharmacokinetics [PK] data) after discontinuation of study therapy
Male subjects must
Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of luspatercept based on multiple-dose PK data) following investigational product discontinuation, even if he has undergone a successful vasectomy
Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
Subject is willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

Subject use of hydroxyurea or other drugs with potential effects on hematopoiesis or ongoing adverse events from previous treatment 112 days immediately up to the enrollment date
Systemic corticosteroids are permitted for nonhematological conditions providing the subject is receiving a stable or decreasing dose for 84 days immediately up to enrollment and is receiving a constant dose equivalent to 10 mg prednisone for the 28 days immediately up to enrollment
Cohort 1 and 2 only: subjects treated with Janus kinase 2 gene (JAK2) inhibitors 112 days immediately up to the enrollment date or if anticipated/substantial likelihood for subject to receive ruxolitinib within the first 168 days on the study
Cohort 3 only: subjects not receiving ruxolitinib
for at least 280 days (40 weeks) without interruptions exceeding 2 consecutive weeks
on a stable daily dose for at least 112 days (16 weeks) immediately up to the enrollment date as part of their standard-of-care therapy
Subject use of ESAs or androgenic steroids 112 days immediately up to the enrollment date
Initiation of iron chelation therapy (ICT) or change with ICT dose within 112 days up to the enrollment date
Subject with anemia from iron deficiency, B12 and folate deficiencies, hemolytic anemia, infection, or bleeding
Pregnant or breastfeeding females
Subject with blood myeloblasts 5%
Subject with major surgery within 8 weeks up to the enrollment date. Subject must have completely recovered from any previous surgery immediately up to the enrollment date
Subject with prior history of malignancies, other than disease under study, unless the subject has been free of the disease for 5 years. However, subject with the following history/concurrent conditions is allowed
Basal or squamous cell carcinoma of the skin
Carcinoma in situ of the cervix
Carcinoma in situ of the breast
Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)
Subject with prior therapy of luspatercept or sotatercept
Subject participation in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices within 30 days immediately up to the enrollment date
Subject with prior hematopoietic cell transplant
Subject with any of the following laboratory abnormalities
Neutrophils < 1 x 109/L
The presence of any of the following will exclude a subject from enrollment
White blood count (WBC) > 100 x 109/L
(with the enrollment date defined as the date in which the subject is assigned
a cohort in Integrated Response Technology (IRT))
Cohorts 1 and 2: < 25 x 109/L
Cohort 3A and 3B: < 50 x 109/L
All Cohorts: > 1000 x 109/L
Estimated glomerular filtration rate < 45 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease [Modification of diet in renal disease (MDRD)] formula)
Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3.0 x upper limit of normal (ULN)
Direct bilirubin 2 x ULN
higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis)
Uncontrolled hyperthyroidism or hypothyroidism
Subject with stroke, deep venous thrombosis, pulmonary or arterial embolism within 6 months immediately up to the enrollment date
Subject with diastolic blood pressure 90 mmHg or systolic blood pressure 140 mmHg measured during the Screening Period despite appropriate treatment
Subject with inadequately controlled heart disease and/or have a known left ventricular ejection fraction <35%
Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (see luspatercept Investigator's Brochure (IB))
Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
Subject with human immunodeficiency virus (HIV), evidence of active infectious Hepatitis B (HepB), and/or evidence of active Hepatitis C (HepC)
Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study
Subject with any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
Subject with any condition or concomitant medication that confounds the ability to interpret data from the study
Subject on anticoagulant therapy not under appropriate control or subject not on a stable dose of anticoagulant therapy for 8 weeks up to the enrollment date
Subject on anagrelide within 28 days immediately up to the enrollment date
Subject with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in hemoglobin of 2g/dL or leading to transfusion of 2 units of packed red cells) in the last 6 months prior to enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note